Physician profile
Stephen Mackerrow
NPI 1225075526
$656.43
in general payments reported to CMS, 2019-2025
15 companies · $98.85 in 2025
The $98.85 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $26.04 · 2021: $11.77 · 2022: $142 · 2023: $51.17 · 2024: $161 · 2025: $98.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $99.10 | 2022 | |
| Abiomed | $79.48 | 2024 | Impella |
| Abbott Laboratories | $65.32 | 2025 | Esprit |
| Novartis Pharmaceuticals Corporation | $56.99 | 2024 | |
| Boston Scientific Corporation | $52.71 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.34 | 2019-2020 | |
| Philips North America LLC | $47.34 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Janssen Pharmaceuticals, INC | $43.96 | 2019-2022 | |
| Pfizer INC. | $39.69 | 2019-2023 | |
| Edwards Lifesciences Corporation | $33.53 | 2025 | Sapien 3 Ultra Resilia |
| Gilead Sciences, INC. | $19.33 | 2019 | |
| Chiesi USA, INC. | $19.08 | 2019 | |
| Amgen INC. | $18.79 | 2019 | |
| Cardiofocus, INC. | $17.00 | 2019 | |
| Bard Peripheral Vascular, INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mackerrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.